BPG is committed to discovery and dissemination of knowledge
Systematic Reviews
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Nov 27, 2026; 18(11): 125240
Published online Nov 27, 2026. doi: 10.4254/wjh.125240
Use of N-of-1 trials in liver diseases: A systematic review
Khalid M AlNaamani, Siham AlSinani, Mohamed El-Kassas
Khalid M AlNaamani, Department of Medicine, Division of Gastroenterology and Hepatology, The Medical City for Military and Security Services, Muscat 111, Oman
Khalid M AlNaamani, Steatotic Liver Diseases Study Foundation in Middle East and North Africa, Cairo 11795, Al Qāhirah, Egypt
Siham AlSinani, Department of Child Health, Sultan Qaboos University Hospital, University Medical City, Muscat 123, Oman
Mohamed El-Kassas, Department of Endemic Medicine, Capital University (formerly Helwan University), Cairo 11795, Egypt
Author contributions: AlNaamani KM contributed to conceptualization, methodology, investigation, data curation, formal analysis, writing the original draft, review and editing, and supervision; AlSinani S contributed to methodology, investigation, data curation, validation, writing the original draft, review, and editing; El-Kassas M. contributed to methodology, writing the original draft, review and editing, and supervision.
AI contribution statement: No AI tool was used in writing this manuscript.
Conflict-of-interest statement: The Authors declare no conflict of interest in relation to this manuscript.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Khalid M AlNaamani, Department of Medicine, Division of Gastroenterology and Hepatology, The Medical City for Military and Security Services, Muscat 111, Oman. noumani73@gmail.com
Received: July 2, 2026
Revised: September 1, 2026
Accepted: November 5, 2026
Published online: November 27, 2026
Processing time: 141 Days and 8.2 Hours
Core Tip

Core Tip: Many rare, chronic, and stable liver diseases are difficult to investigate using conventional randomized controlled trials. N-of-1 trials are randomized, multiple-crossover trials designed to evaluate treatment effects in an individual patient. In this scoping review, we identified only two hepatology studies using this design: One evaluating thiamine in chronic hepatitis B and the other evaluating ursodeoxycholic acid in hepatic sarcoidosis. These findings highlight the underuse of N-of-1 trials as a potentially valuable approach for studying rare, chronic, and stable liver diseases.

Write to the Help Desk